Ipilimumab is a CTLA-4 antibody immune checkpoint inhibitor that works by blocking CTLA-4 and thereby promoting cd8 t cell activation while depleting regulatory t cells. It is used mainly as a combination component in cancer immunotherapy, including regimens with nivolumab for metastatic colorectal cancer, unresectable hepatocellular carcinoma, and neoadjuvant treatment of cisplatin-ineligible muscle-invasive bladder cancer. In a nanoplatform approach, plga co-delivery of ipilimumab with 2-methoxyestradiol was designed to enhance checkpoint immunotherapy by reversing immunosuppressive metabolism and boosting T-cell immunity. Recent literature also links ipilimumab exposure to immune-related toxicity, with a higher hazard of hyperthyroidism reported in real-world cohort analysis. Overall, the evidence highlights ipilimumab as a key CTLA-4–targeting partner in dual-checkpoint strategies, especially with nivolumab, across solid tumors. The Key Facts indicate its role as a combination component in metastatic colorectal cancer, consistent with the comparative efficacy and safety studies in that setting.
Cancer Immunotherapy
- In metastatic colorectal cancer, ipilimumab served as a combination partner with nivolumab in comparative efficacy and safety analyses. (PMID:41934582)
- The drug was incorporated into the plga nanoplatform IM@PLGA to deplete regulatory t cells and enhance cd8 t cell activation for checkpoint immunotherapy. (PMID:41975460)
- Ipilimumab plus nivolumab was evaluated for unresectable hepatocellular carcinoma in the CheckMate 9DW study. (PMID:41981891)
- Neoadjuvant nivolumab with or without ipilimumab was tested in cisplatin-ineligible patients with muscle-invasive bladder cancer. (PMID:41627171)
Safety and Immune-Related Adverse Events
- Real-world cohort data associated immune checkpoint inhibitor use, including ipilimumab, with a higher hazard of hyperthyroidism. (PMID:42012269)
- Cox proportional hazards modeling specifically identified increased hyperthyroidism risk with ipilimumab. (PMID:42012269)
- The bladder cancer neoadjuvant trial provides additional clinical context for combination use in a cisplatin-ineligible population. (PMID:41627171)
- The metastatic colorectal cancer meta-analysis compared nivolumab-based regimens containing ipilimumab, informing benefit-risk assessment. (PMID:41934582)